Observational Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Feb 16, 2023; 11(5): 1058-1067
Published online Feb 16, 2023. doi: 10.12998/wjcc.v11.i5.1058
Analysis of the value and safety of thyroid-stimulating hormone in the clinical efficacy of patients with thyroid cancer
Jian-Jing Liang, Wen-Jing Feng, Ru Li, Run-Tao Xu, Yu-Long Liang
Jian-Jing Liang, Department of Medicine, Hebei University, Baoding 071000, Hebei Province, China
Wen-Jing Feng, Run-Tao Xu, Yu-Long Liang, Department of General Surgery, the Third Hospital of Hebei Medical University, Shijiazhuang 050051, Hebei Province, China
Ru Li, Department of Cardiology, First Hospital of Xinji City, Xinji 052300, Hebei Province, China
Author contributions: Liang JJ and Liang YL were responsible for the concept and writing of the manuscript; Liang JJ and Feng WJ analyzed the data; Feng WJ, Li R and Xu RT were responsible for collecting data and revising the paper; all authors have read and agreed to the published version of the manuscript.
Institutional review board statement: The study was reviewed and approved by Ethics Committee of the Third Hospital of Hebei Medical University.
Informed consent statement: All study participants provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yu-Long Liang, MM, Associate Chief Physician, Associate Professor, Department of General Surgery, the Third Hospital of Hebei Medical University, No. 139 Ziqiang Road, Qiaoxi District, Shijiazhuang 050051, Hebei Province, China. yulongliang2020@163.com
Received: December 5, 2022
Peer-review started: December 5, 2022
First decision: December 26, 2022
Revised: January 4, 2023
Accepted: January 16, 2023
Article in press: January 16, 2023
Published online: February 16, 2023
Abstract
BACKGROUND

Thyroid cancer (TC) is a common malignant tumor in the endocrine system. In recent years, the incidence and recurrence rates of TC have been raising due to increasing work pressure and irregular lifestyles. Thyroid-stimulating hormone (TSH) is a specific parameter for thyroid function screening. This study aims to explore the clinical value of TSH in regulating the progression of TC, so as to find a breakthrough for the early diagnosis and treatment of TC.

AIM

To explore the value and safety of TSH in the clinical efficacy of patients with TC.

METHODS

75 patients with TC admitted to the Department of Thyroid and Breast Surgery of our hospital from September 2019 to September 2021 were selected as the observation group, and 50 healthy subjects were selected as the control group during the same period. The control group was treated with conventional thyroid replacement therapy, and the observation group was treated with TSH suppression therapy. The soluble interleukin (IL)-2 receptor (sIL-2R), IL-17, IL-35 levels, free triiodothyronine (FT3), free tetraiodothyronine (FT4), CD3+, CD4+, CD8+, CD44V6, and tumor supplied group of factor (TSGF) levels were observed in the two groups. The occurrence of adverse reactions was compared between the two groups.

RESULTS

After treatment with different therapies, the levels of FT3, FT4, CD3+, and CD4+ in the observation group and the control group were higher than those before treatment, while the levels of CD8+, CD44V6, and TSGF were lower than those before treatment, and the differences were statistically significant (P < 0.05). More importantly, the levels of sIL-2R and IL-17 in the observation group were lower than those in the control group after 4 wk of treatment, while the levels of IL-35 were higher than those in the control group, and the differences were statistically significant (P < 0.05). The levels of FT3, FT4, CD3 +, and CD4 + in the observation group were higher than those in the control group, and the levels of CD8+, CD44V6, and TSGF were lower than those in the control group. There was no significant difference in the overall incidence rate of adverse reactions between the two groups (P > 0.05).

CONCLUSION

TSH suppression therapy can improve the immune function of patients with TC, lower the CD44V6 and TSGF levels, and improve serum FT3 and FT4 levels. It demonstrated excellent clinical efficacy and a good safety profile.

Keywords: Thyroid-stimulating hormone, Thyroid cancer, Clinical efficacy, Safety profile

Core Tip: Thyroid carcinoma (TC) is the most common cancer in the endocrine system. It has been established that thyroid-stimulating hormone (TSH) stimulates the growth and development of thyroid malignancy, and a higher serum TSH level is associated with the incidence of thyroid cancer and an advanced tumor stage. This study aims to explore the clinical value of TSH in regulating the progress of TC, which can provide a new direction for thyroid therapy.